Mission
Heme Solutions is founded and based in Bethlehem, Pennsylvania.
Our goal is a more healthy, safer and equitable world.
Here’s how we’ll save lives …
Red blood cell transfusions are essential in many medical interventions, but managing donations and the administration of getting blood to patients is a complex and expensive proposition. And despite some 130-million units of blood are donated globally each year, there is still a shortage. By some estimates, the shortage is 120-million units.
Once donated, red blood cells expire with in 45 days. Keeping a fresh supply on-hand is challenging enough, even with the most efficient systems in place. Natural disasters, pandemics, conflict, and under-developed supply chains can disrupt the global supply chain and create needless suffering and even death.
The Heme Solutions has partnered with the inventors of a revolutionary therapy, universal oxygen carrier (UOC) which can be used in place of red blood cell transfusions. UOC has been proven in clinical tests to be a safe and effective replacement therapy. This life-saving solution can be used when traditional blood supplies are not available.
UOC therapy can save lives at a global scale. Some of the advantages of UOC include:
- Compatibility: UOC is compatible with all human blood types.
- Significant cost savings: Produced at scale, the cost of UOC can be significantly less than for producing the traditional red blood equivalent.
- Naturally derived: UOC is designed using a complex carbohydrate technology.
- Extended shelf life: UOC can be stored in dehydrated form for up to 5 years at room temperature with no impairment in efficacy.
- Greater access and efficiency: Because it is shelf stable, UOC can be stored in more ways and in more places than traditional blood.
- Global reach: Because it can be produced at scale and is also shelf stable, AOC can help people in places where access to traditional blood supplies is difficult if not impossible.
Once UOC is approved Heme solutions will manufacture and distribute worldwide. .
